Consejo Nacional de Salud

326
of Lamivudine in Salvage Therapy for Multidrug-Resistant
HIV-1 Infection. Clinica ses
2005; 41:236–42 http://www.journals.
uchicago.edu/doi/full/10.1086/430709
[Consulta: 6 de Noviembre del 2008]
138 Ibíd., 114
139 Fletcher C, Jiang H, Brundage R, Acosta E,
Haubrich R, Katzenstein D, Gulick R,Sex-
Based Differences in Saquinavir Pharmacology
and Virologic Response in AIDS Clinical
Trials Group Study 359, The Journal of Infectious
Diseases 2004; 189:1176–84
140 van Leth F, Phanuphak P, Ruxrungtham
K, Baraldi E, Miller S, Gazzard B, Cahn P,
Lalloo U G, van der Westhuizen P, Malan
D, Johnson M, Santos B R, et al, Comparison
of first-line antiretroviral therapy with
regimens including nevirapine, efavirenz, or
both drugs, plus stavudine and lamivudine: a
randomised open label trial, THE LANCET
• Vol 363 • April 17, 2004, www.thelancet.com.http://linkinghub.elsevier.com/
retrieve/pii/S0140673604159977 [consulta:
18 de Noviembre 2008]
141 Cozzi-Lepri A, De Luca A, Phillips A, Bongiovann
Mi, Di Giambenedetto S, Mena M,
Moioli MC, Arlotti M, Sighinolfi L, Narciso P,
Lichtner M, Cauda R, d’Arminio Monforte
A, A Comparison between Abacavir and
Efavirenz as the Third Drug Used in Combination
with a Background Therapy Regimen
of 2 Nucleoside Reverse-Transcriptase Inhibitors
in Patients with Initially Suppressed
Viral Loads. The Journal of Infectious Diseases
2006; 194:20–8http://www.journals.
uchicago.edu/doi/pdf/10.1086/504265
[consulta: 15 de Noviembre 2008].
142 Ibíd., 114
143 Laurent C, Kouanfack C, Koulla-Shiro S,
Nkou N, Bourgeois S, Calmy A, Lactuock B
et al, Effectiveness and safety of a generic
fixed-dose combination of nevirapine, stavudine,
and lamivudine in HIV-1-infected
adults in Cameroon: open-label multicentre
trial. Lancet 2004; 364: 29–34. http://
linkinghub.elsevier.com/retrieve/pii/
S0140673604165860 [consulta: 25 de
Noviembre del 2008]
144 Berenguer J, González J, Ribera E, domingo
P, Santos J et al., Didanosine, Lamivudine,
and Efavirenz versus Zidovudine,
Lamivudine, and Efavirenz for the Initial
Treatment of HIV Type 1 Infection: Final
Analysis (48 Weeks) of a Prospective,
Randomized,Noninferiority Clinical Trial,
GESIDA 3903, HIV/AIDS • CID 2008:47
(15 October):1083.
145 Nuesch R, Srasuebkul P, Ananworanich J,
Ruxrungtham K, Phanuphak P, Duncombe
CMonitoring the toxicity of antiretroviral
therapy in resource limited settings: a prospective
clinical trial cohort in Thailand. Journal
of Antimicrobial Chemotherapy 2006;
58, 637–644.
146 Masquelier B, Neau D, Boucher S , Lavignolle-
Aurillac V, Schrive MH, Recordon-Pinson P,
Ragnaud JM, FleuryH, Antiretroviral efficacy
and virological profile of a zidovudine/
lamivudine/tenofovir disoproxil fumarato
combination therapy in antiretroviral-naive
patients, Antiviral Therapy 11:827–830
147 Ibíd., 114